News – Page 1150 – Endpoints News

SIGN UP

In a squeaker, FDA AdComm votes for an OK of Cempra’s antibiotic

9 years ago

Alnylam spells out just why it scrapped revusiran following patient deaths; Innocoll shares plunge on PhIII flops

9 years ago

Hillary Clinton's War on Pharma II; A call for common sense reporting on Alzheimer's R&D

9 years ago

Sanofi jumps into a pivotal study for next-gen Pompe drug

9 years ago

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

9 years ago

Clinton’s chief strategist urged tough drug stance that aimed straight for the "cost pain point”

9 years ago

FDA officials: There was “no scientific basis” for Duchenne drug OK as Sarepta complained of “dire financial” ...

9 years ago

Celyad chief blasts Cellectis’ CEO Choulika, claiming he lied about CAR-T patent

9 years ago

SEC subpoenaes BioMarin in drisapersen probe; Job hunting? The FDA has hundreds of open positions

9 years ago

The losers are piling up after today’s big ASH abstract drop

9 years ago

Spark Therapeutics shares slide after a setback on its hemophilia gene therapy study

9 years ago

Investigators sound a safety alarm after 2 patients die of heart condition following checkpoint combo

9 years ago

Merck can’t prove its Alzheimer’s drug works, yet, but it did just explain why it’s spending a fortune on PhIII

9 years ago

Severe adverse events mar the end of Roche’s PhIII for ‘breakthrough’ hemophilia drug

9 years ago

PTC sees higher regulatory risk in fight to keep its Duchenne drug on the European market

9 years ago

CRISPR upstart Casebia picks Sanofi vet Burns as new CEO; On the heels of a trial debacle, Opexa sheds staffers

9 years ago

Buffeted by safety fears, Cempra shares crushed after FDA flags a warning on its antibiotic

9 years ago

Oncolytic contender Turnstone bags a $41M B round to push a successor for Imlygic

9 years ago

On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders

9 years ago

Still pondering an M&A move, Gilead's R&D team outlines a Q3 lineup of setbacks on 3 pipeline drugs

9 years ago

AveXis shares soar after it outlines FDA’s support for a looming pivotal study on SMA

9 years ago

Post-PhIII implosion, Celldex buys oncology drug developer Kolltan in $235M deal

9 years ago

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial

9 years ago

Bon appetit: Cellectis CEO Choulika hosts a gene-edited feast; CRO Medpace adding 650 staffers

9 years ago

First page Previous page 1147 1148 114911501151 1152 1153 Next page Last page